Sep. 9 at 2:20 PM
$ISLMF CAUTION...is warranted and here's why:
The "Regression to the Truth" Risk: Drug development in IPF is a known graveyard for biotechs. In just the last few years, major contenders like ziritaxestat, zinpentraxin alfa, and pamrevlumab all delivered incredibly promising Phase 2 data, only to suffer disastrous, multi-million-dollar failures in Phase 3.
Short Evaluation Window: The trial evaluated efficacy at only 12 weeks. IPF is a highly unpredictable, progressive, and fatal disease. Regulatory bodies like the FDA typically look for sustained efficacy over 52 weeks to prove a therapy can truly disrupt long-term lung decay. Small sample sizes (71 patients) can also lead to statistical anomalies that flatten out when expanded to thousands of diverse patients globally.
